Provided by Tiger Trade Technology Pte. Ltd.

Vir Biotechnology, Inc.

11.18
+0.53004.98%
Post-market: 11.02-0.1600-1.43%17:11 EDT
Volume:1.74M
Turnover:19.28M
Market Cap:1.89B
PE:-6.59
High:11.26
Open:10.70
Low:10.54
Close:10.65
52wk High:11.94
52wk Low:4.82
Shares:168.65M
Float Shares:130.00M
Volume Ratio:1.11
T/O Rate:1.34%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6972
EPS(LYR):-3.1619
ROE:-26.08%
ROA:-14.51%
PB:1.92
PE(LYR):-3.54

Loading ...

AstraZeneca To Invest $2 Billion In Summit And Co-Develop Drugs; Shares Jump After Hours

Options & Short Sell
·
Sep 29

Pharmaceutical Stocks Jump. Moderna, Eli Lilly up over 3%; Novavax, Pfizer up Around 2%; Merck, Novo Nordisk up over 1%

Tiger Newspress
·
Sep 24

Vir Biotechnology (VIR) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Sep 22

Vir Biotechnology CEO to Join Morgan Stanley Global Healthcare Conference Fireside Chat

Reuters
·
Sep 01

Vir Biotechnology on Track for Record Winning Streak

Dow Jones
·
Aug 19

The Bull Case For Vir Biotechnology (VIR) Could Change Following A Sudden Swing To Quarterly Profitability

Simply Wall St.
·
Aug 17

Olema Pharmaceuticals Names Jason O’Byrne CFO

Reuters
·
Aug 13

Vir Biotechnology Inc : Morgan Stanley Cuts Target Price to $25.00 from $27.00

THOMSON REUTERS
·
Aug 06

Vir Biotechnology price target lowered to $19 from $21 at Leerink

TIPRANKS
·
Aug 06

Vir Biotechnology (VIR) Gets a Buy from Barclays

TIPRANKS
·
Aug 06

Vir Biotechnology, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Vir Biotechnology Swings to FY26 Q2 Net Income of $80.1 Million; Revenue Rises to $238.9 Million

Reuters
·
Aug 06

Vir Biotechnology Q2 Revenue Up, Beats Estimates on Astellas Payment

Reuters
·
Aug 06

Vir Biotechnology Q2 EPS $0.47 Beats $0.18 Estimate, Sales $238.946M Beat $216.456M Estimate

Benzinga Earnings
·
Aug 06

Vir Biotechnology Q2 EPS USD 0.48

Reuters
·
Aug 06

Corrected-Vir Biotechnology Q2 EPS USD 0.47 (Corrects Amount)

THOMSON REUTERS
·
Aug 06

Vir Biotechnology Inc Expected to Post Earnings of 33 Cents a Share - Earnings Preview

Reuters
·
Aug 04

Earning Preview: Vir Biotechnology, Inc. Q2 revenue expected to increase by 7,852%, institutional views are bullish

Earnings Agent
·
Jul 30

Vir Biotechnology Names Brent Sabatini Interim Principal Financial Officer as CFO Exits

Reuters
·
Jul 24

Vir Biotechnology - Appoints Brent Sabatini as Interim Principal Financial Officer Effective July 23

THOMSON REUTERS
·
Jul 24